Download Ohne Titel - Univ.-Prof. Dr. Michael Gnant

Univ. Prof. Dr. Michael Gnant
234
Originalarbeiten
- 27 -
Gnant M, Steger GG
Fighting overtreatment in adjuvant breast cancer therapy
Lancet 2009; 374: 2029-30
235
IF: 30,758
Gnant M
Bisphosphonates in the adjuvant treatment of early breast cancer
Breast Cancer Res 2009; 11: S17
236
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleaoni M, Coombes C,
Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R, for the Aromatase Inhibitor
Overview
Group of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
Meta-analysis
J Clin Oncol 2010; 28: 509-18
237
IF: 4,696
IF: 18,970
Kaufmann M, von Mickwitz G, Morrow M, The Biedenkopf Expert Panel Members
Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendation from an
International Expert Panel
IF: 5,131
Cancer 2010; 116: 1184-9
238
Gnant M, Eidtmann H
The anti-tumor effect of bisphosphonates: ABCSG-12, ZO-FAST and more...
Crit Rev Onc Hem 2010; 74: S2-6
239
IF: 4,589
Lux MP, Nowitzki C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Mammakarzinom: Bisphosphonate in der Adjuvanz - auch aus gesundheitsökonomischer Sicht eine
sinnvolle Therapie
IF: 0,342
Geburtsh Frauenheilk 2010; 70: 8-11
240
Delea T, Taneja C, Sofrygin O, Kaura S, Gnant M
Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women with
Hormone-Responsive Early Breast Cancer
IF: 2,790
Clin Breast Cancer 2010; 4: 267-74
241
Gnant M
The evolution of bone-targeted therapies: Introduction
Sem Oncol 2010; 37: S1
242
IF: 3,355
Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Results of the Zometa® Cost-utility model for the German healthcare system based omn the results
of the ABCSG-12 study
IF: 1,153
Onkologie 2010; 33: 360-8
Univ. Prof. Dr. Michael Gnant
243
Originalarbeiten
- 28 -
Gnant M
Neue Studiendaten zur endokrinen Langzeittherapie
Gyn Spectrum 2010; 1: 4-6
IF: 0,000
244
Starlinger P, Moll H, Assinger A, Nemeth C, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann S, Gnant M, Brostjan
C
Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vitro
processes
IF: 4,701
J Thromb Hemosta 2010; 8: 1809-19
245
Gnant M
Can oral bisphophonates really reduce the risk of breast cancer in healthy women?
J Clin Oncol 2010; 28: 3548-51
246
IF: 18,970
Gampenrieder S, Bartsch R, Scheuer R, Pluschnig U, Dubsky P, Gnant M, Zielinski C, Steger G
Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and
metastatic breast cancer
IF: 0,364
Breast Care 2010; 5: 158-162
247
Gnant M
Neoadjuvant Treatment and Breast Conserving Surgery - a success of clinical research in breast
cancer
IF: 0,000
Wien Med Wochenschr 2010; 160: 163-6
248
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C,
Peto R, Bijker N, Solin L, Darby S
Overview of the ransomized trials of radiotherapy in ductal carcinoma in situ of the breast
J Natl Cancer Inst Monogr 2010; 41: 162-77
249
IF: 14,697
Gnant M, Dubsky PC
Closing in on the unknown enemy
Lancet Oncol 2010; 11:402-3
250
IF: 17,764
Bartsch R, Steger G, Gnant M, Ziebermayr R
Breast Cancer: Rank Ligand Inhibition
Breast Care 2010; 5: 320-325
251
IF: 0,364
Schoppmann S,Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P
HER-2/neu-expression correlates with vascular endothelial growth factor-C and lymphangiogenesis
in llymph node positive breast cancer
IF: 6,452
Ann Oncol 2010; 21: 955-60
Univ. Prof. Dr. Michael Gnant
252
Originalarbeiten
- 29 -
Neville-Webbe H, Gnant M, Coleman R
Potential anticancer properties of bisphosphonates
Semin Oncol 2010; 7: S53-65
IF: 3,355
253
Mouridsen H, Lonning P, Beckmann M, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B,
Gnant M
Use of aromatase inhibitors and bisphosphonates as an anti-cancer therapy in postmenopausal
breast cancer
IF: 2,976
Expert Rev Anticancer Ther 2010; 11: 1825-36
254
Gnant M, Hadji P
Prevention of bone metastases and management of bone health in early breast cancer
Breast Cancer Research 2010; 12: 216
IF: 4,859
255
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-DeschmannM , Rech-Weichselbraun I, Burghuber C,
Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R
Modulation of plasma complement by the initial dose of epirubicin / docetaxwl therapy in breast
cancer and its predictive value
IF: 4,831
Br J Cancer 2010; 103: 1201-8
256
Gnant M
10 years of ATAC: one question answered, many others unresolved
Lancet Oncology 2010; 11: 1109-10
257
IF: 17,764
Gnant M
Adjuvant Bisphosphonate therapy in postmenopausal breast cancer patients
Breast Care 2010; 5: 298-304
258
IF: 0,364
Hadji P, Gnant M, Aapro M, Lipton A, Coleman R
Dosing of Zoledronic Acid throuout the treatment continuum in breast cancer
Crit Rev Oncol Hematol 2011; 79:175-88
IF: 4,411
259
Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, Poestlberger S, Lang A, Gnant M, Greil R, on behalf of the
ABCSG
Sentinel Node Biopsy after primary chemotherapy in breast cancer: A note of caution from results
from ABCSG-14
IF: 1,643
Breast J 2011; 17: 230-8
260
Gnant M
Adjuvant Zoledronic Acid reduces disease recurrence in breast cancer:
Antitumor effects on the seed and the soil
Curr Cancer Ther Rev 2011; 7: 111-18
IF:
Univ. Prof. Dr. Michael Gnant
261
Originalarbeiten
- 30 -
Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between
chemotherapy and anti-VEGF treatment
IF: 5,946
Neoplasia 2011; 13; 5: 419-27
262
Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Wolbank S, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R,
Hantusch B, Keller T, Nagy-Bojarski K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S,
Madlener
S, Vonach
C, Davidovits
A, Nosaka
H, Haemmerle M,
Viola K, Dolznig
H, Schreiber
M, Nader lymph
A, Mikulits
W,
Lipoxigenase
mediates
Invasion
of intrametastatic
lymphatic
vessels
and propagates
node
metastasis of human mammary carcinoma xenografts in mouse
IF: 13,069
J Clin Invest 2011; 132: 2000-12
263
Sahora K, Kuehrer I, Fitzal F, Schindl M, Koelblinger C, Goetzinger P, Gnant M
NeoGemTax - Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetatasized pancreatic cancer
IF: 2,362
World J Surg 2011; 35: 1580-9
264
Gnant M
Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific concepts
Breast Disease 2011; 33: 71-81
265
IF:
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts
Disease Markers 2011; 31: 55-65
IF: 1,642
266
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengruth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G,
Bauernhofer T, Eidtmann H, Eiermann W., Steger G, Kwasny W, Dubsky P, Hochreiner G,, Forsthuber EP, Fesl C, Greil R,
on
behalf ofendocrine
the ABCSG therapy plus zoledronic acid in premenopausal women with early breast cancer:
Adjuvant
62-month follow-up from ABCSG-12
IF: 22,590
Lancet Oncol 2011; 12: 631-41
267
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer C, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V,
Jänicke F, Schmidt M, Kölbl H, Rody A, kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS,
Henning
G, Gehrmann
M, GnantofM distant recurrence in estrogen recpetor-positive HER2-negative breast
A new molecular
predictor
cancer adds independent information to conventional clinical risk factors
IF: 7,742
Clin Cancer Res 2011; 17: 6012-20
268
Gnant M
Zoledronic Acid in Breast Cancer: Latest Findings and Interpretations
Ther Adv Med Oncol 2011; 3: 293-301
269
IF:
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thuerlimann B, Senn HJ, & Panel members
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen
International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
IF: 6,425
Ann Oncol 2011; 22: 1736-47
Univ. Prof. Dr. Michael Gnant
270
Originalarbeiten
- 31 -
Gnant M, Harbeck N, Thomssen C
St. Gallen 2011: Summary of the consensus discussion
Breast Care 2011; 6: 136-41
271
IF: 0,446
Fitzal F, Riedl O, Mittlboeck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M
Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant therapy: A
retrospective single centre cohort study
IF: 4,431
Breast Cancer Res Treatm 2011; 127: 121-128
272
Öfner D, DeVries A, Schaberl-Mosef R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp K, Fastner G, Keil F, Eisterer W,
Jäger R, Offner F, Gnant M, Thaler J, for the TAKO 05/!BCSG R02 Trial Investigators
Preoperative oxaliplatin, capecitabine and external beam readiotherapy in patients with newly
diagnosed, primary operable, cT3NxM0 low rectal cancer - a Phase II study
IF: 3,561
Strahlenther Oncol 2011; 187: 100-7
273
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Relevance of breast hormone receptors and other factors to the efficacy of adjuvant tamoxifen:
patient-level meta-analysis of randomised trials
IF: 38,278
Lancet 2011; 378: 771-84
274
Gnant M, Piccart-Gebhart M, Goldhirsch A, Baselga J, Cameron D, Di Leo A, Dowsett M, Gelber M, von Mickwitz G,
Wadvogel C, Straehle C
Developing an international network for breast cancer research: the Breast International Group (BIG)
experience
IF: 13,069
Clin Invest 2011; 1(5): 623-28
275
Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Discrimination between circulating endothelial cells and blood cell populations with overlapping
phenotype reveals distinct regulation and predictive potential in cancer therapy
IF: 5,946
Neoplasia 2011; 13: 980-90
276
Pfeiler G, Koenigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer C, Poestlberger S, Steger G, Seifert M, Dubsky P,
Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M
Impact of Body Mass Index on the efficacy of endocrine therapy in premenopausal patients with
breast cancer: An analysis of the prospective ABCSG-12 trial
IF: 18,372
J Clin Oncol 2011; 29: 2653-9
277
Hadji P, Aapro M, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast
cancer: Practical guidance for prevention and treatment
IF: 6,425
Annals of Oncology 2011; 22: 2546-55
278
Gnant M
Targeted therapies: Adjuvant bisphosphonates - an option with low estrogen?
Nature Reviews Clinical Oncology 2011; 8: 698-9
IF: 11,963
Univ. Prof. Dr. Michael Gnant
279
Originalarbeiten
- 32 -
Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A; Breast International Group; North
American Breast Cancer Group Endocrine Working Group
Pregnancy after breast cancer: if you wish, ma'am
Breast Cancer Res Treatm 2011; 129: 309-17
IF: 4,431
280
Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Pecl-Radosavlejvid M,
Ba'ssalamah A, Zielinski C, Gnant M
NeoGemOx - Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer
IF: 3,103
Surgery 2011; 143: 311-20
281
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast
cancer mortality in women with early breast cancer: analysis of individual patient data on 10,801
women
in 17 randomised
trials
IF: 38,278
Lancet 2011;
378: 1707-16
282
Bago-Horvath Z, Rudas M, Dubsky P, Singer C, Dietze O, Greil R, Jelen A, Boehm G, Jasarevic Z, Lang A, Gruber C,
Poestlberger S, Filipits M, Gnant M, on behalf of the ABCSG
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal
women with low proliferating breast cancer
IF: 7,742
Clin Cancer Res 2011;17: 7828-34
283
Gnant M
Bisphosphonates in the adjuvant treatment of breast cancer - Rationale and clinical data
Clin Invest 2011; 1: 97-107
IF: 13,069
284
Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann
K, Mader R, Gnant M, Zielinski C, Steger G
Impact of anti-HER2 therapy on overall survival in HER2-positive metastatic breast cancer patients
with brain metastases
IF: 5,042
Br J Cancer 2012; 106: 25-31
285
Gnant M, Steger GG
Dual HER2 inhibition in breast cancer treatment
Lancet 2012; 379; 596-8
286
IF: 38,278
Knauer M, Gnant M, Fitzal F, Panel Members
Results of the first Austrian multidisciplinary expert panel on controversies in local treatment of breast
cancer
IF: 0,446
Breast Care 2012; 7: 61-66
287
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant
M
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and
Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and
Colorectal
Cancer
Study
(ABCSG)
IF: 4,166
Ann Surg Oncol
2012;
19:Group
1808-17
Univ. Prof. Dr. Michael Gnant
288
Originalarbeiten
- 33 -
Gnant M
Zoledronic Acid in the treatment of early stage breast cancer: Is there a final verdict?
Curr Oncol Reports 2012; 14:35–43
IF: 2,545
289
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M,
Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L
Recommendations from an International Consensus Conference on the Current Status and Future of
Neoadjuvant Systemic Therapy in Primary Breast Cancer
IF: 4,166
Ann Surg Oncol 2012; 19: 1508-16
290
Hadji P, Aapro M, Costa L, Gnant M
Antiresorptive treatment options and bone health in cancer patients - safety profile and clinical
considerations
IF: 6,054
Cancer Treatm Rev 2012; 38, 815-24
291
Baselga J, Campone M, Piccart M, Burris HA, Rugo, HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck
JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu C, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
N Eng J Med 2012; 366: 520-9
292
IF: 53,298
Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F
Objetively measured breast symmetry has no influence on quality of life in breast cancer patients
Eur J Surg Oncol 2012; 38: 130-6
293
IF: 2,444
Resch G, DeVries A, Oefner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J, on behalb of the ABCSG
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally
advanced rectal cancer - A two stage phase II clinical trial
IF: 5,580
Radiother Oncol 2012; 102: 10-3
294
Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise T, Lipton A, Aapro MS
Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?
Cancer Treatm Rev 2012; 38: 798-806
295
IF: 6,054
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses
of long-term outcome among 100 000 women in 123 randomised trials
IF: 38,278
Lancet 2012; 379: 432-44
296
Gnant M, Dubsky P, Hadji P
Bisphosphonates: prevention of bone metastases in breast cancer
Recent Results Cancer Res. 2012;192:65-91
IF: 2,000
Univ. Prof. Dr. Michael Gnant
297
Originalarbeiten
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Guzudar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C,
Robertson J
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Ann Oncol 2012; 23: 1378-86
298
- 34 -
IF: 6,425
Fitzal F, Mittlboeck M, Steger G, Bartsch G, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M
Neoadjuvant chemotherapy increases the rate of breast conservation on lobular-type breast cancer
patients
IF: 4,166
Ann Surg Oncol 2012; 19: 519-26
299
Dubsky P, Jakesz R, Mlineritsch B, Poestlberger, Graz2, Kwasny W, Tausch C, Samonigg H, Haider K, Fitzal F, Singer C,
Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M, on
behalf
of the and
ABCSG
Taxoxifen
Anastrozole as a sequencing strategy: A randomized controlled trial in
postmenopausal patients with endocrine-responsive early breast cancer: Final results from the
Austrian
Breast
and30:
Colorectal
IF: 18,372
J Clin Oncol
2012;
722-8 Cancer Study Group
300
Gnant M
Anticancer activity of bisphosphonates in breast cancer
Anticancer Agents Med Chem 2012; 12: 114-22
301
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F,
Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.
Brain metastases free survival differs between breast cancer subtypes
Br J Cancer 2012; 106: 440-6
302
IF: 3,144
IF: 5,042
Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Fitzal F, Dubsky P, Jesch B, Birner P
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive
breast cancer
IF: 4,431
Breast Cancer Res Treatm 2012; 134: 237-44
303
Gnant M, Balic M, Petru E, Raunik W, Singer CF, Steger GG, Watzke IM, Brodowicz T
Treatment of bone metastases in patients with advanced breast cancer
Breast Care 2012; 7: 92-8
304
IF: 0,446
Coleman RE, Gnant M, Morgan G, Clezardin P
Bone Targeted Agents: Effects on disease progression and mortality in solid tumour and
haematological cancers
IF: 14,700
J Nat Cancer Inst 2012; 1059-67
305
Gnant M
Overcoming endocrine resistance in breast cancer: importance of mammalian target of rapamycin
(mTOR) inhibition
IF: 2,652
Expert Rev of Anticancer Ther 2012; 12: 1579-89
Univ. Prof. Dr. Michael Gnant
Originalarbeiten
- 35 -
306
Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F,
Gnant M, Zielinski CC, Steger GG
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with
metastatic breast cancer
IF: 4,944
Eur J Cancer 2012; 48: 1932-8
307
Hadji P, Coleman R, Gnant M, Green J
The impact of menopause on bone and implications for breast cancer growth and metastasis
Ann Oncol 2012; [in press]epublished Jun22
308
IF: 5,536
Gnant M, Clezardin P
Direct and indirect Anticancer Activity of Bisphosphonates: A review of published literature
Cancer Treatm Rev 2012; 38: 407-15
309
Hubalek M, Gnant M, Bartsch R, Kapp K, Lang A, Lax S, Lukas P, Neunteufel W, Reitsamer R, Sandbichler P, Schrenk P,
Tamussino K, Pristauz G, Tschmelitsch J, Singer C, Zeimet A, Marth C
Axilladissektion bei positivem Sentinel-Lymphknoten - Ergebnisse Innsbrucker Konsuskonferenz
Geburtsh Frauenheilk 2012; 72:299–304
310
IF: 6,054
IF: 0,823
Gnant M, Beermann B
8th European Breast Cancer Conference (EBCC-8)
Breast Care 2012; 7: 170-6
311
IF: 0,446
Gnant M
Adjuvant bisphosphonates: a new standard of care?
Curr Opin Oncol 2012, 24:635-42
IF: 4,101
312
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D,
Schmidt M, Gehrmann M, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M
EndoPredict improves the prognostic classification derived from common clinical guidelines in ERpositive, HER2-negative early breast cancer
IF: 6,425
Ann Oncol 2012, [in press]online Oct 3, 2012
313
Arnold T, Micklmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, BachleitnerHofmann T, Oehler R
Increase in plasma HMBG-1 after the initial dose of epirubicin/docetaxel in breast cancer is
associated with response to therapy
IF:
BMC Cancer Eur J Clin Invest 2013; [in press]
314
Gnant M
The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced
Breast Cancer
IF: 2,545
Curr Oncol Rep 2013; 15: 14-23
Univ. Prof. Dr. Michael Gnant
Originalarbeiten
- 36 -
315
Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,
Barni S, Deschamp V
The impact of educational materials on compliance and persistence rates with adjuvant aromatase
inhibitor treatment: first year results from the Compliance of ARomatase Inhibitors AssessmenT In
Daily
practice
through
Educational approach (CARIATIDE) Study
IF:
Gyn Oncol
2013
[submitted]
316
Singer CF, Holst F, Steurer S, Burandt E, Samonigg H, Lax S, Jakesz R, Rudas M, Stöger H, Greil R, Dietze O, Sauter G,
Filipits M, Simon R, Gnant M, on behalf of ABCSG
Oestrogen receptor alpha gene (ESR1) copy number increase is an independent predictor of distant
recurrence in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast
cancer
IF:
[submitted]
2013
317
Gnant M, Pfeiler G, Stoeger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger
G, Samonigg H, Fesl C, Jakesz R, on behalf of the ABCSG
The predictive impact of body mass indey on the efficacy of extended adjuvant endocrine treatment
with anastrozole in postmenopausal patients with breast cancer - an analysis of the randomized
ABCSG
6a trial
IF:
Eur J Cancer
2013 [submitted]
319
Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W, Pabinger I
Microparticle-associated tissue factor activity in patients with pancreatic cancer: Correlation with
clinicopathological features
IF: 3,020
Eur J Clin Invest 2013; 43: 277-85
320
Gnant M
Role of Bisphosphonates in postmenopausal women with breast cancer
Breast Cancer Research 2013 [submitted]
IF:
321
Burris HA, Lebrun F, Hugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi G, Komorowski A,
Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Rixxi JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Health-related Quality of Life of Advanced Breeast Cancer Patierns treated with Everolimus plus
Exemestane versus Placebo plus Exemestane in the Phase 3, randomized, controlled, BOLERO-2
trial
IF:
Cancer
2013 [submitted]
322
Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F
Predictors of Morbidity in Breast-Conserving Surgery of Early-Stage Breast Cancer Using the Clavien
Dindo Classification
IF:
Ann Surg 2013 [submitted]
323
Pfeiler G, Stoeger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U,
Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil
R,
Fesl C,
M, on
behalf of the ABCSG
Efficacy
of Gnant
tamoxifen
± aminoglutethimide
in normal weight and overweight postmenopausal patients
with hormone-receptor positive breast cancer – an analysis of 1509 patients of the ABCSG-06 trial
IF:
Eur J Cancer 2013 [submitted]
324
Goetz M, Suman V, Ames M, Gnant M, Filipits M, Hoskin T, Safgren S, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O,
Lang A, Offner F, Reynolds C, Weinshilboum R, Ingle J
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Study Group trial
(ABCSG) 8
IF: 7,742
Clin Cancer Res 2013; 19: 500-7
Univ. Prof. Dr. Michael Gnant
Originalarbeiten
- 37 -
325
Hortobagyi G, Piccart M, Rugo H, Burris H, Noguchi S, Gnant M, Pritchard K, Campone M, Neven P, Pistilli B, Shtivelband
M, Provencher L, Masuda N, Bauly H, Mukhopadhyay P, El-Hashimy M, Sahmoud T, Lebwohl D, Baselga J
Everolimus for postmenopausal women with advanced breast cancer: Long-term results of the
BOLERO-2 Phase III trial
IF:
Cancer 2013 [submitted]
326
Yardley DA, Noguchi S, Prichard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Capone M, Pistilli B, Piccart M,
Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Fend W, Cahana A, Taran T, Sahmoud T, Lebwohl D, Rugo HS
BOLERO-2: Final Progression-Free Survival Analysis
J Clin Oncol 2013 [submitted]
IF:
327
Bartsch R, Berghoff AS, Rudas M, Dubsky P, DeVries C, Sattlberger C, Mader MR, Sparber C, Fitzal F, Gnant M,
Rottenfusser A, Zielinski CC, Preusser M, Steger GG
Taxanes and Trastuzumab compared to oral Vinorelbine and Trastuzumab in HER2-overexpressing
metastatic breast cancer patients
IF:
[submitted]
328
Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Laengle F, Oefner D, Mischinger HJ,
Pratschke J, Gnant M, Fuegger R
Preparing for prospective clinical trials - a national initiative of an excellence registry for consecutive
pancreatic cancer resections
IF:
Surgery 2013 [submitted]
329
Hadji P, Coleman R, Gnant M
Bone effects of mTOR inhibition with everolimus
Crit Rev Oncol/Hematol 2013 [in press]
IF:
330
Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri
D
Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and
Meta-Analysis
IF:
Oncologist. 2013 Feb 12. [Epub ahead of print]
331
Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch
R
Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic
Breast Cancer
IF:
Breast J. 2013 Jan 27. doi: 10.1111/tbj.12070. [Epub ahead of print
332
Heitzer E, Mach M, Filipits M, Resel M, Graf R, Weiszenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F,
Boehm G, Hoefler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N
Promoter methylation status of PCDH10, SPARC, and UCHL1 predict survival in stage II colorectal
cancer patients treated with or without 5-fluorouracil-based chemotherapy
IF:
Clin Cancer Res 2013 [submitted]
333
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M,
Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Everolimus reduced bone marker levels and progressive disease in bone in BOLERO-2
J Nat Cancer Inst 2013; [in press] online Feb 16, 2013
IF: 14,700
Univ. Prof. Dr. Michael Gnant
Originalarbeiten
- 38 -
334
Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Gnant M, Dimopoulos MA,
Bartsch R
Aromatase inhibitors with or without a gonadotropin-releasing hormone analogue in male breast
cancer patients: a case series
IF:
Ann Oncol 2013 [submitted]
349
Riss S, Laggner U, Strohschneider M, Hayden H, Dubsky P, Bachleitner-Hofmann T, Gnant M, Stift A, Friedl J
The Impact of IL 4 in Dendritic Cell Differentiation
J Leucocyte Biology 2013
349
IF:
Sahora K, Schindl M, Werba G, Kuehrer I, Fitzal F, Friedl J, Goetzinger P, Gnant M
Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not
affect mortality and morbidity after pancreatic resection
IF:
2013 [submitted]
999
Dubsky P, Gnant M, Handl-Zeller S, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Taucher S, Resch A, Pötter R,
Jakesz R, for the ABCSG
Postmastectomy radiotherapy for breast cancer
[in preparation]
999
Gnant M, Bauernhofer T, Mittlboeck M, Hausmaninger H, Kubista E, Samonigg H, Kwasny W, Mlineritsch B, Steger G,
Mader I, Jakesz R, for the ABCSG
The impact of participiation in randomized clinical trials on survival of women with breast cancer
[in preparation]
999
IF:
IF:
Jackisch C, Robertson JF, Gnant M
Extending the endocrine options for premenopausal women with breast cancer
Eur J Cancer 2011 [in press]
999
IF:
Baudraxler F, Gnant M, Krestan CR
A case of cecal volvulus diagnosed by 64-row-multi-detector CT
Abdom Imaging 2011; [submitted]
999
IF:
Exner R, ...... Gnant M
Austrian CARIATIDE
[in preparation]
IF: